Multiply Labs and Legend Biotech Accelerate Cell Therapy

After several years spent perfecting its robotic cell therapy manufacturing system, Multiply Labs has secured its first collaboration with a major cell therapy developer, Legend Biotech. Both companies believe the collaboration has the potential to lead to faster and smoother adoption of robotic technology compared to traditional automation approaches.

While many of the details of the deal are still unknown, Fierce Pharma notes that Legend is set to receive “priority access” to Multiply’s automated systems as part of the collaboration .

“The idea is to use robots to perform the same tasks that people used to do, but in a more efficient and precise way. The goal is for this technological change to not negatively affect the cells that are being cultivated and processed,” explained Fred Parietti, co-founder and CEO of Multiply Labs.

Multiply Labs promotes the use of robots in developing cell therapies

Multiply Labs has repeatedly pointed out the high manufacturing costs of manual processes, which require a lot of labour and, in many cases, there is a shortage of qualified workers in this field. Therefore, the system, composed of modules in which robotic arms operate different instruments already widely used for the production of cell therapies, represents a significant leap forward.

Multiply Labs’ CEO said the partnership with Legend as a commercial developer of cell therapies represents an “important” new phase in the company’s path. Paretti also said that more partnerships with both manufacturers and developers of cell therapies are on the way.

__

(Featured image by Possessed Photography via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in ConSalud.es. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us